Intratumoral immunotherapy delivers an immune-directed treatment within a tumour. Local effects, immune responses and control of other lesions need separate evidence.
Intratumoral describes a route into a tumour, while immunotherapy describes the intended immune-directed action. Products, injection methods and accompanying treatments differ. A lesion-based method needs an identified safely accessible site; local delivery does not guarantee confined exposure or systemic safety.
An in-situ vaccination strategy is one possible use of local tumour material, rather than a synonym for every injection. Evidence must distinguish injected-lesion changes, controlled immune assays, uninjected-lesion outcomes and the whole regimen’s benefits and harms.
Shares itRECIST (response criteria for injected immunotherapy), Cytokines & engineered cytokines, Oncolytic viruses, Immune checkpoint inhibitors.
Shares Talimogene laherparepvec, Oncolytic viruses, Immune checkpoint inhibitors.
Shares Talimogene laherparepvec, Cytokines & engineered cytokines, Oncolytic viruses, Immune checkpoint inhibitors.
Shares itRECIST (response criteria for injected immunotherapy), Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/